# Ivan Burkov

> Ivan Burkov is a seed investor at Inkef backing Therapeutics and Biotechnology. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Inkef](https://shizune.co/investors/profile/inkef-capital)
- Total investments: 2
- Last investment: May 2025
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/ivanburkov

Ivan Burkov is a seed investor at Inkef focused on Therapeutics and Biotechnology. Ivan Burkov

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Therapeutics | 2 | 100% |
| Biotechnology | 2 | 100% |
| Health Care | 1 | 50% |
| Medical Device | 1 | 50% |
| Pharmaceutical | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 50% |
| Series B | 1 | 50% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Denmark | 1 | 50% |
| The Netherlands | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Salvia BioElectronics | Salvia is an innovative startup active in the emerging field of bioelectronics. The name Salvia is derived from the Latin word salvere, which means to stay healthy. In addition, the Salvia-plant has been used to treat headaches, pain, and mental disorders over centuries. Salvia's mission is to deliver bioelectronic solutions that restorehealth for people suffering from chronic migraine. Salvia aims to provide drug-free solutions that are effective and inherently side-effect free and make the novel solutions widely accessible. The Salvia team consists of experienced entrepreneurs, engineers and scientists with diverse professional backgrounds and proven track-record throughout the medical device industry (Sapiens, Medtronic, Philips, St Jude, BioSensors International, Kyphon, etc). | $60.1M | Series B | May 27, 2025 |  |
| Draupnir Bio | Draupnir Bio intends to develop a new type of cholesterol-lowering medicine that prevents blood clots in the heart more effectively than the current medicine. The company is developing a platform for exploring the glycome to develop novel therapeutics, based on array technology, protein chemistry, and advanced carbohydrate chemistry. The company isable to synthesize, screen, and select highly potent and specific heparan sulfate glycomimetic drug candidates in cardiovascular, inflammatory, and infectious diseases. | $13.2M | Seed | Jul 17, 2024 |  |

2 of 2 investments shown.

## Co-investors
- [Innovation Industries](https://shizune.co/investors/profile/innovation-industries) — VC Fund, 2 deals together
- [BOM](https://shizune.co/investors/profile/brabantse-ontwikkelings-maatschappij-bom) — VC Fund, 1 deal together
- [Dolby Family Ventures](https://shizune.co/investors/profile/dolby-family-ventures) — VC Fund, 1 deal together
- [European Innovation Council Fund](https://shizune.co/investors/profile/european-innovation-council-fund) — VC Fund, 1 deal together
- [Export and Investment Fund](https://shizune.co/investors/profile/export-and-investment-fund) — VC Fund, 1 deal together
- [Gilde Healthcare](https://shizune.co/investors/profile/gilde-healthcare-partners) — VC Fund, 1 deal together

## About Inkef

VC Fund · Amsterdam, The Netherlands

Inkef is a venture capital firm based in Amsterdam, backing promising early stage companies in Europe. Inkef takes pride in being a patient, long-term investor with the ability to support companies through several rounds of funding. From the early stages of a technology or life science venture, Inkef supports entrepreneurs building their ideas intosuccessful international businesses.Investment areas: Technology and Healthcare

5 contacts available at Inkef.

| Name | Title | Profile |
| --- | --- | --- |
| Frank Lansink | Partner | https://shizune.co/investors/profile/frank-lansink |
| Thijs Cohen Tervaert | Partner | https://shizune.co/investors/profile/thijs-cohen-tervaert |
| Derk Arts | Founder | https://shizune.co/investors/profile/derk-arts-c179 |
| Ivan Burkov | Principal | https://shizune.co/investors/profile/ivan-burkov |
| Simone Botti | Partner | https://shizune.co/investors/profile/simone-botti |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Ivan Burkov invest in?

Ivan Burkov invests primarily in Therapeutics, Biotechnology and Health Care startups, most often at Seed and Series B stage. Most of the 2 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Ivan Burkov last invest?

The most recent investment recorded for Ivan Burkov closed in May 2025. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co